Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Latest Research · GLP-1 and Hair

Does the weight-loss jab cause hair loss?
A bidirectional answer from two 2026 TriNetX studies

In June 2026 the Journal of the American Academy of Dermatology published two large TriNetX cohort studies whose conclusions look contradictory but are in fact complementary: Herrera et al. observed in ~1 million matched patients that semaglutide (Ozempic / Wegovy) and tirzepatide (Mounjaro / Zepbound) users had a 1.77× higher risk of new-onset telogen + anagen effluvium at 1 year and 2.41× higher risk of androgenetic alopecia anytime, with only modest BMI change — suggesting rapid weight loss cannot fully explain the signal. Hill et al., in 1,171 matched pairs of patients with scarring alopecia (CCCA, frontal fibrosing alopecia, lichen planopilaris, folliculitis decalvans), found that starting a GLP-1 / GIP agonist after diagnosis was associated with 30–47% lower utilization of anti-inflammatory and corticosteroid treatments. The two studies target different populations (general users vs existing scarring-alopecia patients) and different outcomes (new-onset vs treatment burden). This dual-track article integrates patient education + clinical analysis with 7 patient FAQs and a detailed mechanistic dual-pathway breakdown.

Reminder ·This article reviews Herrera et al. and Hill et al., two TriNetX retrospective cohort studies published in the same June 2026 issue of the Journal of the American Academy of Dermatology, plus related FAERS / case-report evidence and mechanistic literature. Observational studies are limited by ICD-10 coding accuracy, adherence data, missing weight-change information, and other confounders, and do not equal RCT evidence. Decisions to start or stop semaglutide / tirzepatide should be made with your endocrinology or weight-management physician on a case-by-case basis, especially for those with concomitant thyroid disease, PCOS, family history of androgenetic alopecia, or prior alopecia areata. This site does not engage in medical advertising and does not endorse any clinic, hospital, drug, or procedure.

One-page TL;DR — three numbers to know

1.77× / 2.41× — In the general user population, 1-year new-onset risk of telogen + anagen effluvium is 1.77× and androgenetic alopecia anytime risk is 2.41× vs metformin controls. From Herrera 2026 JAAD's ~1 million patient TriNetX cohort, statistically significant after propensity score matching.
30–47% ↓ — In patients already diagnosed with scarring alopecia (CCCA, frontal fibrosing alopecia, lichen planopilaris, folliculitis decalvans), starting a GLP-1 / GIP agonist was associated with a 30–47% reduction in anti-inflammatory treatment utilization (intralesional steroids, topical steroids, calcineurin inhibitors, hydroxychloroquine, antihistamines, antibiotics). From Hill 2026 JAAD's 1,171 matched pairs.
Not just "weight loss too fast" — In Herrera's cohort BMI dropped only ~1.81 kg/m² over 1 year — modest weight change — yet hair loss still rose significantly. This suggests GLP-1RA's effect on hair follicles is not purely a 'rapid weight loss → telogen effluvium' pathway; a direct metabolic / IGF-1 / inflammation-modulation pathway also exists. So even at moderate weight loss, hair loss risk is still elevated.

Why is the weight-loss jab being linked to hair loss?

Semaglutide received US FDA approval for type 2 diabetes in 2017 and obesity (Wegovy) in 2021; tirzepatide for diabetes (Mounjaro) in 2022 and obesity (Zepbound) in 2023. The SURMOUNT-5 trial (Aronne 2025 NEJM) showed tirzepatide produced 20.2% mean weight loss over 72 weeks, exceeding semaglutide's 13.7%. The class has gone from diabetes drug to the dominant weight-loss option, with over 15 million prescriptions globally.

As prescriptions surged, dermatology clinics began seeing patients complaining of new-onset hair loss after starting these injections. The FDA Adverse Event Reporting System (FAERS) showed a notable rise in alopecia reports since 2022 (Godfrey 2025 JEADV). Burke 2025 JAAD was the first retrospective cohort to quantify higher hair loss rates in GLP-1RA users. But these early signals were limited by small cohort sizes, residual confounding, and single-manufacturer reporting bias. Herrera 2026 JAAD's TriNetX analysis at the 1-million-patient scale with PSM is currently the strongest evidence.

Meanwhile, an opposite signal quietly emerged: case reports (Morrissette 2024 Cureus) of tirzepatide improving refractory folliculitis decalvans, and Desir 2025 JAAD on GLP-1 agonists modulating CCCA treatment response. Hill 2026 JAAD was the first systematic 5-year evaluation in 1,171 matched pairs of patients with existing scarring alopecia — finding treatment utilization actually decreased. Same drug class: risk for those without alopecia, but apparently helpful for those with inflammatory scarring alopecia? This contrast is the most intriguing aspect of the two studies.

For patients: 7 most-asked questions

Q1. Will Ozempic / Mounjaro really cause hair loss?

Yes — the risk is higher, but not everyone experiences hair loss.

Q2. Will it grow back? Is it telogen effluvium or AGA?

Two patterns:

Q3. When does shedding start, and when does it stabilize?

Herrera timeline data: at 6 months TE+AE risk has not reached significance; at 1 year RR 1.77 is significant; anytime risk reaches 2.42.

Q4. Is it just because of fast weight loss?

Not entirely. The classic fast-weight-loss→telogen-effluvium pathway is well known, but in Herrera's cohort BMI dropped only ~1.81 kg/m² over 1 year — a modest change — yet hair loss still rose significantly.

Q5. I already have alopecia areata / AGA — can I take it?

Individualized assessment needed. Even with PSM controlling for known hair-loss confounders (PCOS, hypothyroidism, iron deficiency, prior spironolactone/finasteride), AA risk still rose 1.53× and AGA risk 1.96×. This is not an absolute contraindication; weigh against metabolic benefits with your endocrinology team, possibly adding prophylactic minoxidil.

Q6. I have scarring alopecia (FFA / CCCA / lichen planopilaris) — will it actually help?

Preliminary evidence suggests yes. Hill 2026 JAAD found that in 1,171 PSM pairs with pre-existing scarring alopecia, starting GLP-1/GIP therapy was associated with 30-47% lower 5-year utilization of intralesional steroids, topical steroids, antihistamines, hydroxychloroquine, calcineurin inhibitors, and antibiotics.

Q7. Should I stop the drug? How should I discuss with my doctor?

Three steps:

Below: clinical write-up · for clinicians

Herrera 2026 JAAD — new-onset hair-loss risk (GLP-1RA users vs metformin)

Herrera HO and Bordeaux JS (Case Western Reserve), JAAD 2026 June 1826-1827. The largest observational study to date evaluating GLP-1RA and new-onset alopecia.

Study design

  • Source: TriNetX US database (de-identified multi-centre EMR) + TriNetX worldwide for replication.
  • Inclusion: ≥18 y, ≥2 prescriptions of semaglutide or tirzepatide.
  • Control: metformin users with no prior GLP-1RA exposure.
  • Excluded: prior chemotherapy / immunosuppressant exposure (avoid hair-cycle confounding); patients with the outcome before the analysis window.
  • PSM covariates: age, race, sex, ethnicity, BMI, overweight/obesity, PCOS, type 2 diabetes, hypothyroidism, hyperlipidemia, hypertension, iron-deficiency anaemia, iron deficiency, nutritional deficiency, spironolactone use, finasteride use — i.e., all known alopecia confounders balanced.
  • Sample (after PSM): US 576,250 pairs / Worldwide 619,732 pairs. The largest cohort of this type.
  • Outcomes (ICD-10): TE L65.0, AE L65.1, AA L63, AGA L64, other non-scarring alopecia L65. Three timepoints: 6 mo, 1 y, anytime.

Primary findings

Figure 1: GLP-1RA users vs metformin — new-onset hair-loss risk (RR 95% CI)GLP-1RA users vs metformin — new-onset hair-loss risk (TriNetX US)Source: Herrera et al. JAAD 2026, Table I (n = 576,250 pairs, after PSM)RR = 1.0 (no difference)0.51.52.02.5+TE + AETelogen + anagen effluvium6m RR 1.30 (NS)1y RR 1.77anytime RR 2.42Other non-scarring alopecia(L65 umbrella category)6m RR 1.591y RR 1.98anytime RR 2.14Alopecia areata (AA)L636m RR 1.421y RR 1.53anytime RR 1.726 mo (NS)1 yr (significant)anytime (significant)Bar = 95% CI, dot = point estimate
Figure 1 — Herrera 2026 JAAD: semaglutide / tirzepatide users vs metformin controls; new-onset hair loss RR with 95% CI, stratified by time (6 mo / 1 y / anytime). Only TE+AE at 6 mo is non-significant; all other estimates significant. AGA not shown here — 6 mo RR 1.79, 1 y 1.96, anytime 2.41 (largest signal). After PSM, US n = 576,250 pairs.

Key observation: BMI change

Herrera reported BMI trajectories after PSM:

TimepointGLP-1RA group BMIMetformin group BMIDifference
index event37.20 ± 7.9733.90 ± 8.48+3.30
6 months35.94 ± 7.8532.58 ± 7.74+3.36
1 year35.39 ± 7.8832.46 ± 7.71+2.93
anytime34.76 ± 7.8732.22 ± 7.71+2.54

The 2.5–3.4 BMI gap persisted throughout; GLP-1RA group only dropped 1.81 by 1 y and 2.44 anytime — far below the 13–20% loss seen in SURMOUNT-5 / STEP RCTs. Possible reasons: (a) incomplete weight documentation in TriNetX EMR; (b) lower real-world adherence; (c) some patients on diabetic doses, not obesity doses. Whatever the cause, the modest BMI change proves the increased alopecia signal cannot be fully explained by rapid weight loss — there must be a direct GLP-1RA metabolic / signaling pathway as well.

Hill 2026 JAAD — treatment-need changes in scarring alopecia

Hill MA et al. (Case Western Reserve + Cleveland Clinic), JAAD 2026 June 1833-1834. The first systematic evaluation of GLP-1 / GIP agonist effects on healthcare resource utilization (HRU) in patients with existing scarring alopecia.

Study design

  • Source: TriNetX 2017-2025.
  • Inclusion: 18-90 y, diagnosed with one of four scarring alopecias: CCCA (L66.81), frontal fibrosing alopecia (L66.12), lichen planopilaris (L66.1), folliculitis decalvans (L66.2).
  • Additional: ≥8 healthcare visits (CPT 99202-99215, 99385-99397) — minimizes healthcare-engagement differences.
  • Treatment cohort: started semaglutide or tirzepatide within 1 year after alopecia diagnosis.
  • Control: PSM with matched demographics, alopecia subtype, baseline treatment, and comorbidities. n = 1,171 per cohort.
  • Outcome: 5-year RR for using various scarring alopecia therapies.

Primary findings — treatment-use rates drop significantly

Figure 2: GLP-1 / GIP agonist users vs controls — scarring alopecia treatment HRU RRGLP-1 / GIP users — impact on scarring-alopecia treatment utilizationSource: Hill et al. JAAD 2026, Figure 1 (n = 1,171 pairs, after PSM)0.30.50.7RR = 1.01.5Calcineurin inhibitor(tacrolimus、pimecrolimus)RR 0.53 (0.41-0.68)HydroxychloroquineRR 0.60 (0.47-0.75)Antibiotic(doxycycline, minocycline, etc.)RR 0.65 (0.57-0.75)Topical steroid(clobetasol, betamethasone, etc.)RR 0.67 (0.59-0.77)Intralesional triamcinoloneInjection (IL-triamcinolone)RR 0.72 (0.59-0.88)Antihistamine(fexofenadine、cetirizine)RR 0.76 (0.58-0.98)Methotrexate0.78 (NS)TNF-α inhibitor(adalimumab, etc.)0.65 (NS)← Significant decreaseSignificant increase →Significant decrease (95% CI entirely left of 1)Non-significant (CI crosses 1)
Figure 2 — Hill 2026 JAAD: GLP-1 / GIP agonist vs control among existing scarring alopecia patients; 5-year RR for using various therapies. Six categories show significant reduction (green); methotrexate and TNF-α inhibitors did not reach significance due to small refractory-case subset (grey CI), not necessarily ineffective. n = 1,171 matched pairs.

Cohort baseline + PSM balance

Hill cohort characteristics (n = 1,171 each):

  • Heavily female: 85.65% vs 87.27% female (SMD 0.0474) — reflecting the female predominance of scarring alopecia (especially CCCA, FFA).
  • High average BMI: 35.9 vs 35.2 kg/m² (SMD 0.0916) — obese range, explaining why this population was prescribed GLP-1 / GIP.
  • Race: White 66.01% vs 62.93%, Black 24.85% vs 29.80% (SMD 0.1113)
  • Type 2 DM: 21.52% vs 22.11% (SMD 0.0145, well balanced).

The two studies are complementary, not contradictory

Place both studies in a 2×2 matrix and the apparent contradiction resolves:

Figure 3: Herrera and Hill — population × outcome 2×2 matrix2×2 matrix — populations × outcomes from the two studiesSame drug, different populations, different outcomes — apparent conflict but actually complementaryAlready has scarring alopeciaCCCA / FFA / LPP / FDGeneral population (no scarring alopecia)Diabetic / obese patientsDisease courseNew-onset hair lossHill 2026n = 1,171 PSM pairsTreatment use ↓Steroids, HCQ, TCI, antibiotics↓ 30–47%(N/A here)General population never had itCan worsen scarring alopecia— No study —(insufficient data)Already-diagnosed scarring-alopecia groupWhether it triggers new-onset?Non-scarring hair loss — not reportedHerrera 2026n > 1.15M PSMNew-onset hair loss ↑TE / AGA / AA / other1y RR 1.53–1.98The two studies occupy different quadrants and complement each other. The same GLP-1 / GIP is therapeutic for inflamed scarring-alopecia patients but a risk for the otherwise hair-healthy general population.
Figure 3 — 2×2 matrix of the two studies. Hill occupies top-left (existing scarring alopecia + disease activity), Herrera occupies bottom-right (general users + new-onset). The two diagonal cells (no studies yet) are future research directions. Not 'good vs bad effect' but 'different populations, different questions, different answers.'

Mechanism hypothesis — GLP-1RAs affect hair follicles via two parallel pathways

GLP-1 receptors (GLP-1R) were initially thought to be confined to pancreatic β cells, pituitary, and cardiovascular tissue. Recent immunology work (Wong & Drucker 2025 J Clin Invest) has shown GLP-1R expression on macrophages, T cells, bone marrow stroma, hepatic Kupffer cells, and even skin hair follicles. The effect on follicles cannot be explained solely by 'gut hormone → appetite suppression → weight loss.' Splitting the mechanism into two independent, sometimes opposing pathways best explains the paradox.

Figure 4: GLP-1RA dual-pathway hypothesis on hair follicleGLP-1RA → hair follicle — dual-pathway mechanism hypothesisBoth pathways run in parallel but produce opposite net outcomes in different populationsGLP-1RAsemaglutide / tirzepatidePathway A: anti-inflammatory(beneficial for inflamed cohorts)• GLP-1R binds macrophages / T cells• NF-κB ↓ → TNF-α / IL-6 ↓• Th17-axis modulation → IL-17 ↓• Systemic metabolic syndrome ↓• Insulin sensitivity ↑、CRP ↓• Perifollicular inflammation ↓→ Scarring-alopecia disease improvementPathway B: metabolic / endocrine reset(triggers susceptible cohorts)• Caloric deficit → mass follicle telogen entry• Inadequate protein → amino acids / keratin ↓• IGF-1 axis ↓ → shorter anagen phase• SHBG ↑ → free androgen shift• Accelerates AGA expression• Stress hormone (cortisol) shift→ New-onset TE / AE / AGA / AABoth pathways run in parallel; net outcome depends on patient constitutionHas inflammatory scarring alopeciaPathway A dominant(treatment need ↓ 30-47%)Pathways balancedNo hair-loss predisposition, stable weight(minimal hair impact)Susceptible (family alopecia / PCOS)Pathway B dominant(new-onset hair loss ↑ 1.5-2.4×)
Figure 4 — Dual-pathway hypothesis. Pathway A (anti-inflammatory, green): GLP-1R on macrophages and T cells suppresses NF-κB → reduces TNF-α / IL-6 / IL-17 → less perifollicular inflammation. Explains Hill's finding of reduced HRU in scarring alopecia. Pathway B (metabolic / endocrine reset, red): caloric deficit, IGF-1 axis decline, SHBG change, accelerated AGA expression and TE. Explains Herrera's finding of new-onset alopecia. Both pathways operate; the net effect depends on patient inflammation status and susceptibility.

Pathway A: anti-inflammatory + immune modulation

GLP-1RA's anti-inflammatory effects are now documented across multiple rheumatologic / autoimmune diseases (Bilgin 2025 Autoimmun Rev). Key molecular pathways:

  • GLP-1R is expressed on macrophages and T cells. GLP-1 binding activates cAMP / PKA, inhibits NF-κB signaling, and decreases downstream TNF-α, IL-1β, IL-6, and IL-17 expression.
  • The core pathology of scarring alopecia (especially CCCA, FFA, LPP) is perifollicular lymphocytic infiltrate plus fibrosis of arrector pili. Reducing local Th1 / Th17 response slows permanent follicular destruction.
  • Systemic metabolic syndrome and obesity amplify baseline inflammatory cytokines (Bapat 2022 Nature demonstrated this in inflammatory disease). Improving metabolic status partially relieves the systemic inflammatory background.
  • A folliculitis decalvans case report (Morrissette 2024 Cureus) documented marked improvement on tirzepatide — n=1 but mechanistically consistent. Desir 2025 JAAD observed similar modulation in CCCA.

Pathway B: metabolic / endocrine reset stressing the follicle

This pathway combines the classic 'TE mechanism + AGA acceleration':

  • Caloric deficit / rapid weight loss: similar to very-low-calorie diet (VLCD) or post-bariatric-surgery effects — hair follicles enter telogen en masse (catagen → telogen), manifesting 3-6 months later as diffuse hair loss. Classic TE mechanism.
  • Protein and micronutrient deficiency: GLP-1RA suppresses appetite, and inadequate protein intake limits keratin synthesis substrates (L-cysteine, methionine), worsening TE. Recommend ≥1.2 g/kg ideal body weight protein/day.
  • IGF-1 axis decline: weight loss reduces IGF-1, a key growth factor maintaining anagen. Lower IGF-1 shortens anagen, hair enters catagen / telogen earlier.
  • SHBG rises, free androgen profile shifts: weight loss raises SHBG. Females may see reduced free testosterone; in males, some studies show altered local DHT metabolism in follicles. In AGA-susceptible individuals, this may accelerate AGA expression. Herrera's AGA anytime RR of 2.41 — the highest among outcomes — aligns with this.
  • Physiologic stress response: GI side effects and nausea on initiation may contribute via cortisol fluctuation and TE.

Why can both pathways operate simultaneously?

The key is 'in whom' and 'which follicles':

  • Pathway A is salient where follicles are already inflamed — scarring alopecia patients have pathologically activated Th1 / Th17 infiltrates; anti-inflammatory intervention has immediate measurable benefit.
  • Pathway B is salient with global metabolic reset — affects all users, but only those with vulnerable follicle baseline (AGA family history, PCOS, poor nutritional reserve) develop a clinically detectable phenotype.
  • In the same patient both pathways may operate: someone with AGA susceptibility plus LPP may see LPP improvement via pathway A while AGA accelerates via pathway B. Net effect must be evaluated case-by-case.

Risk timeline — when is it riskiest?

Figure 5: New-onset hair-loss RR accumulating over timeNew-onset hair-loss RR accumulates over treatment timeData: Herrera 2026 JAAD Table I (TriNetX US, n = 576,250 pairs)1.01.52.02.5No difference6 months1 yearanytimeTE + AEOther non-scarringAndrogenetic alopecia (AGA)Alopecia areata (AA)TE+AE 6m NSHigher = greater risk; solid bar = 95% CI significant, dot = point estimate. AGA carries the highest cumulative risk of the 4 types (anytime 2.41×).
Figure 5 — New-onset alopecia RR over time. AGA (deep red) rises earliest and most steeply; TE+AE (light red) is non-significant at 6 mo but climbs to 2.42 by anytime. AA (yellow) shows smaller magnitude. Clinically, the 1-year visit should include hair loss screening, especially in patients with AGA family history.

Study limitations

Common limitations of both TriNetX studies:

  • Observational retrospective, not RCT, cannot prove causality. Confounding by indication may persist — e.g., GLP-1RA users may have more severe metabolic syndrome.
  • Relies on ICD-10 coding accuracy. Clinical diagnoses of TE / AGA / AA are often over-coded (L65.0 used loosely); coding errors affect true RR estimates.
  • No trichoscopy / dermoscopy images, cannot quantify severity (no SALT, no hair count, no anagen/telogen ratio).
  • Adherence and dose data incomplete. Herrera defined exposure as ≥2 prescriptions; Hill as initiation within 1 y of alopecia diagnosis. TriNetX has no actual administration records.
  • Hill's disease severity data is missing; reduced HRU may partly reflect patients feeling improved and not returning, not necessarily true disease improvement.
  • Hill's subtype-specific analyses (CCCA, FFA, LPP, FD separately) were underpowered. Future prospective studies need adequate per-subtype power.
  • Herrera reported weight changes; Hill did not fully report. Cannot evaluate dose-response between weight loss magnitude and treatment response / alopecia.

Clinical take-aways

  1. In general users, 1-year TE + AE risk is 1.77× and AGA anytime is 2.41× after starting semaglutide / tirzepatide; risk accumulates over time.
  2. BMI dropped only ~1.8 kg/m² / 1 y; rapid weight loss cannot fully explain alopecia. Mechanism must include direct GLP-1R action on follicles + IGF-1 axis + SHBG shift.
  3. In scarring alopecia (CCCA, FFA, LPP, folliculitis decalvans), starting GLP-1 / GIP reduces anti-inflammatory treatment utilization by 30–47%; hypothesised mediation via macrophage / T-cell GLP-1R and systemic NF-κB suppression.
  4. Pre-prescription counseling should ask: alopecia family history, PCOS, thyroid history, prior AA / TE. Susceptible patients warrant preventive counseling + 3–6-month photographic follow-up.
  5. If hair loss develops: (a) differentiate TE vs AGA acceleration; (b) labs to rule out confounders (ferritin, TSH, vitamin D, ANA); (c) assess protein intake; (d) consider minoxidil 5% + standard AGA management; (e) joint risk-benefit review with endocrinology / weight-management — do not unilaterally stop the drug.
  6. In scarring alopecia patients needing weight reduction, GLP-1 / GIP can be considered as an adjunctive option, decided case-by-case with endocrinology, but cannot replace existing standard-of-care (steroids / HCQ / antibiotics).

Further reading: see «7 Hair Loss & Male Pattern Baldness Myths» for baseline myths, «Alopecia Areata: Complete Patient Guide» for autoimmune AA. Discuss standard AGA therapy (Minoxidil / Finasteride) with your dermatologist.

References

  1. Primary sources
  2. Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol. 2026;94(6):1826-1827. [Source]
  3. Hill MA, Yang AC, Bergfeld W, Piliang M. Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX. J Am Acad Dermatol. 2026;94(6):1833-1834. [Source]
  4. GLP-1RA and hair loss evidence
  5. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141-1143. [Source]
  6. Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153-e154. [Source]
  7. Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024;63(9):1128-1130.
  8. Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: a scoping review. J Am Acad Dermatol. 2024;91(1):166-168.
  9. GLP-1 / GIP benefits in scarring alopecia
  10. Desir N, Encarnacion IN, Schell N, Anusionwu I, Ogunleye TA, Taylor SC. GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2025;93(3):771-773. [Source]
  11. Morrissette K, Hansen S, Pavlis M, Murray JC. Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report. Cureus. 2024;16(12):e76267. [Source]
  12. Wyche J, Senna M, Aguh C. Approach to scarring alopecia. JAMA Dermatol. 2025;161(12):1281-1282.
  13. Mechanism and anti-inflammatory
  14. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025;135:e194751.
  15. Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions. Autoimmun Rev. 2025;24:103864.
  16. Bapat SP, Whitty C, Mowery CT, et al. Obesity alters pathology and treatment response in inflammatory disease. Nature. 2022;604:337-342.
  17. Andrzejczak K, Sternak A, Witkowski W, Ponikowska M. Inflammation-driven molecular ageing in chronic inflammatory skin diseases: is there a role for biologic therapies? Cells. 2025;14:1442.
  18. GLP-1RA RCTs and head-to-head
  19. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36.